

8 5/16/03 83/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

11			
In re applica	tion of: Alvaro et al.		
Serial No.:	10/089,964	Group Art Unit	:: 1624
Filed:	May 8, 2002	Examiner:	To be assigned
For:			
Commission Washington,	er for Patents , D.C. 20231		
	SUPPLEMENTAL INFORM	ATION DISCLOSUI	RE STATEMENT
Applica Examiner and	ents request that the references identified officially made of record in accordance	d on Form PTO-1449 appe ce with the provisions of 3°	nded hereto be considered by the 7 CFR 1.97
[] Cop [] A co is su attac	ies of the references are enclosed ies of the references were submitted in the opy of the International Search Report, abmitted herewith. All of the publication of the PTO-1449 and Applicants unice by the International Bureau.	which issued on Internations cited in the Internations	al Search Report are listed on the
A. [X]	The Information Disclosure States he filing date of the above application or before the mailing occurs last. 37 CFR 1.97(b).	ition or date of entry into th	being filed within three months of ne national stage of an international on the merits, whichever event
В. []	The Information Disclosure States the filing date of the above application 1.491 of an international application merits, whichever event occurred	cation or the date of entry i ion or after the mailing date	is being filed after three months of nto the national stage as set forth in § c of the first Office Action on the g date of either:
	(1) a final action under § 1.113 or(2) a notice of allowance under § 1.3	11,	•
whi	chever occurs first.		
[]	Applicant hereby certifies that each its Statement was cited in a communicati application not more than three month	on from a foreign patent of	fice in a counterpart foreign
[]	Applicant elects the option to pay the f Disclosure Statement under § 1.97(c) (ee set forth in 37 CFR 1.17 \$240.00).	(p) for submission of an Information
C. []	The Information Disclosure Statemen 1.113, or a notice of allowance under issue fee. Also enclosed is a copy of Publication No. In accordance with the requirements of	§ 1.311, whichever occurs the International Search Re	first, but before the payment of the

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

[] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

[X] Please charge required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

Lorie Ann Morgan

Registration No. 38,181

Date: 6 Feb 2003

GlaxoSmithKline

Five Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709

Telephone: (919) 483-8222 Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY LEKET NO. PI3806USW APPLICANT: Alvaro et al.		SERIAL NO. 10/089,964	
						10/089,904	
0	PA			FILING Date: GROUP			
l: ~	67			May 8, 2002		1624	
- (FB)	7 2003 (3)	U.S. PA	TENT DO	CUMENTS			
Examine Initials	atent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriat
	Number						
`		Cor	ntinue on p	age		<u> </u>	
		FOREIGN	PATENT	DOCUMENTS			
	Document Number	Publication Date		Country	Class	Subclass	Translation Yes No
3	WO 97/36593	October 9, 1997	PCT				
		•					
		Co	ntinue on	page	- Dana Numi	on Eta)	
	OTHER DOCU	MENTS (Includin	g Author,	Title, Journal-Dat	e, Page Num	ber, Etc.)	
		-					
		· C	ontinue on	page			*
EXAMINER				r 5	DATE	CONSIDERED	